Dr. Joseph T. Coyle Named
Chair of SyneuRx’s Scientific Advisory Board

Renowned neuroscientist known for his groundbreaking discoveries in psychiatric disorders joins advisory board to drive clinical development efforts

Press Release

July 25, 2022

LOS ANGELES and NEW TAIPEI CITY, Taiwan, July 25, 2022 – SyneuRx™ International (TPEX:6575), a global biotech company focused on the development of new classes of drugs for COVID-19 and multiple major central nervous system disorders, today announced that Joseph T. Coyle, M.D., is joining SyneuRx as chairman of the company’s new Scientific Advisory Board. In his role, Coyle will be responsible for advising, leading, and advancing the company’s strategic growth towards novel neuropsychiatric treatments.

“We are honored to have Dr. Coyle joining our newly formed Scientific Advisory Board. His groundbreaking research has changed the face of psychiatric neuroscience, and illuminated core neurological mechanisms underlying Alzheimer’s disease, Huntington’s disease, and especially schizophrenia,” said Emil Tsai, M.D., Ph.D., M.A.S., founder, chairman and CEO of SyneuRx. “His half-century of devoted research in developmental neurobiology, mechanisms of neuronal vulnerability and psychopharmacology will be an asset in helping us to shape our future clinical programs and to achieve our key growth objectives.”

Joseph Coyle has 50 years’ worth of clinical medical experience while serving as a leadership mentor to faculty and students at Johns Hopkins School of Medicine as well as at Harvard Medical School. He has led a distinguished career in neurobiology and psychopharmacology, focused on the neurotransmitter glutamate, which is an area of research Coyle has earned distinction in.

In addition to Coyle’s role at SyneuRx, he serves as professor emeritus of the Department of Psychiatry of Harvard Medical School, continues to write research papers, and sits on several international scientific boards. He was also past president of the Society for Neuroscience, American College of Neuropsychopharmacology, and past editor of JAMA Psychiatry for over a decade. Prior to these roles, he served on the Johns Hopkins School of Medicine faculty for many years, where he was a Distinguished Service Professor of Child Psychiatry and director of the Division of Child and Adolescent Psychiatry. Dr. Coyle received his medical degree from Johns Hopkins School of Medicine in 1969, where he earned several awards. He and Dr. Tsai developed a strong mentor-mentee relationship while working at Harvard, and in 1997 were jointly honored with the Kemp Fund Award from the American Psychiatric Association.

​​“I am eager to join SyneuRx at such a pivotal time for mental health care globally. The COVID-19 pandemic has truly brought behavioral health care disparities to the forefront, and I am grateful to be a part of the solution by helping pave the way toward novel treatments,” said Coyle. “I look forward to helping the company accelerate its already very impressive growth.”

SyneuRx’s Scientific Advisory Board has been created to offer strategic direction and guidance on aspects of scientific endeavors, including developing new therapies, conducting research, and ensuring that quality standards are met. Over the coming years, the company plans to introduce leading experts who will join the Scientific Advisory Board to assist in building the company’s long-term scientific strategy.

Coyle will begin his role with SyneuRx this month.

Media Contact

SyneuRx Press Office

Phone: (818) 696-8800                

Email: media@syneurx.com

About SyneuRx

SyneuRx International (TPEX:6575) is a clinical-stage global biotech company focused on the development of new classes of drugs for COVID-19 and multiple major central nervous system (CNS) disease conditions. Founded in 2013, SyneuRx is poised to bring change-making pharmaceuticals to market with a robust, promising pipeline of seven investigational drugs for CNS disorders and two for COVID-19 – eight of which are currently in phase 2 and phase 3 clinical trials with the U.S. Food and Drug Administration. The company’s mission is to infuse a scientific and humanistic approach into its research and development of safe, effective, and accessible therapies for patients suffering from disorders such as schizophrenia, dementia, depression, as well as COVID-19 and other RNA-encoded viruses. Dedicated to taking a safety-first approach with its research and development by focusing on well-established lead compounds as well as natural sources and plant substances to treat or prevent illness, SyneuRx has received Breakthrough Therapy Designations and Orphan Drug Designations from the FDA for two of its novel CNS therapeutics. To learn more, visit syneurx.com.

Disclosure Notice

The information contained in this release is as of July 25, 2022. SyneuRx assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about SyneuRx’s efforts to combat COVID-19 as well as flu and the company’s investigational oral antiviral candidate Pentarlandir® (including qualitative assessments of available data, potential benefits, expectations for clinical trials, advanced purchase agreements, the anticipated timing of data readouts, regulatory submissions, regulatory approvals or authorizations, planned investment and anticipated manufacturing, distribution and supply), involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the ability to produce comparable clinical or other results including efficacy, safety and tolerability profile observed to date, in additional studies or in larger, more diverse populations following commercialization; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when any drug applications or submissions to request emergency use or conditional marketing authorization for any potential indications for Pentarlandir may be filed in any jurisdictions and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when regulatory authorities in any jurisdictions may approve any such applications for Pentarlandir, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pentarlandir, including development of products or therapies by other companies; risks related to the availability of raw materials for Pentarlandir; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand, which would negatively impact our ability to supply the estimated numbers of courses of Pentarlandir within the projected time periods; whether and when additional purchase agreements will be reached; the risk that demand for any products may be reduced or no longer exist; uncertainties regarding the impact of COVID-19 on SyneuRx’s business, operations and financial results; and competitive developments.